ASX:VBSVectus Biosystems Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vectus Biosystems Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. Vectus Biosystems Limited was founded in 2005 and is based in Rosebery, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Vectus Biosystems. Previous Next 2.5 Community Rank Outperform VotesVectus Biosystems has received 2 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVectus Biosystems has received 2 “underperform” votes. (Add your “underperform” vote.)Community SentimentVectus Biosystems has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vectus Biosystems and other stocks. Vote “Outperform” if you believe VBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VBS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVectus Biosystems does not currently pay a dividend.Dividend GrowthVectus Biosystems does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vectus Biosystems insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:VBS Previous Symbol CUSIPN/A CIKN/A Webwww.vectusbiosystems.com.au Phone61 2 9662 4144Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$346.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA($0.16) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive VBS News and Ratings via Email Sign-up to receive the latest news and ratings for VBS and its competitors with MarketBeat's FREE daily newsletter. Vectus Biosystems (ASX:VBS) Frequently Asked Questions Has Vectus Biosystems been receiving favorable news coverage? Press coverage about VBS stock has been trending somewhat negative on Sunday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vectus Biosystems earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutVectus Biosystems. Who are some of Vectus Biosystems' key competitors? Some companies that are related to Vectus Biosystems include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV) and Cannabics Pharmaceuticals (CNBX). View all competitors. Who are Vectus Biosystems' key executives? Vectus Biosystems' management team includes the following people: Dr. Karen Annette Duggan, CEO & Exec. DirectorProf. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC, ConsultantMr. Robert John Waring BEc, CA, FCIS, FFin, FAICD, Company Sec. What is Vectus Biosystems' stock symbol? Vectus Biosystems trades on the ASX under the ticker symbol "VBS." How big of a company is Vectus Biosystems? Vectus Biosystems has a market capitalization of $0.00 and generates $346.00 in revenue each year. What is Vectus Biosystems' official website? The official website for Vectus Biosystems is www.vectusbiosystems.com.au. How can I contact Vectus Biosystems? The company can be reached via phone at 61 2 9662 4144. This page was last updated on 5/31/2020 by MarketBeat.com Staff
